Despite having no data until today on the 10 patients with PDAC enrolled in this trial, three out of seven patients with KRAS-mutated colorectal cancer with available tumor response evaluation achieved tumor reduction (all with stable disease by RECIST) [80]. Here, KRAS is linked to neoplasm.